AiTan (rivoceranib) / Jiangsu Hengrui Pharma, HLB Bio Group, Bukwang Pharma, Advenchen - LARVOL DELTA

Biomarkers of response to camrelizumab combined with apatinib: an analysis from a phase II trial in recurrent/metastatic nasopharyngeal carcinoma. (PubMed, Br J Cancer) - P2 | "We established a model that could predict the prognosis of combined therapy. The model could predict outcomes and reflect the systemic immune and inflammatory status, which is beneficial for risk stratification and therapeutic modification."

Biomarker • IO biomarker • Journal • P2 data • Epstein-Barr Virus Infections • Nasopharyngeal Carcinoma • Oncology • Solid Tumor • CD8

A gelable polymer loaded with curcumin and apatinib absorbed in gelatin sponge delays postoperative residual tumor growth. (PubMed, Sci Rep) - "Moreover, GS-CT loaded Cur and Apa (GS-CT-CA) delayed postoperative residual tumor growth in intraperitoneal and subcutaneous postoperative mouse models. These findings demonstrated that our gel carrier system significantly prevents postoperative residual tumor growth because of enhanced drug accumulation and sustained drug release at the tumor site."

Journal • Oncology • Solid Tumor

Camrelizumab combined with apatinib plus irinotecan as a second-line treatment in advanced or metastatic esophageal squamous cell carcinoma patients. (PubMed, BMC Cancer) - "CAM combined with apatinib plus IRT as a second-line treatment exhibits acceptable efficacy and safety in advanced or metastatic ESCC patients. The model that combines clinical and radiomic features has the greatest ability to predict the survival of advanced or metastatic ESCC patients."

Journal • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Fatigue • Hematological Disorders • Leukopenia • Neutropenia • Oncology • Squamous Cell Carcinoma • Thrombocytopenia

Hepatic artery infusion chemotherapy combined with camrelizumab and apatinib as conversion therapy for patients with unresectable hepatocellular carcinoma: a single-arm exploratory trial. (PubMed, BMC Cancer) - P2 | "The combination of HAIC, camrelizumab, and apatinib as conversion therapy shows promising clinical benefits and a manageable safety profile in patients with uHCC. Future randomized controlled trials are warranted."

Journal • Hepatocellular Cancer • Oncology • Solid Tumor

HAIC in Combination with Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Advanced HCC (clinicaltrials.gov) - P=N/A | N=97 | Active, not recruiting | Sponsor: First Hospital of China Medical University

Checkpoint inhibition • Combination therapy • Metastases • New trial • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor

Multiple primary tumors patient developed microsatellite stable gastric cancer after cadonilimab treatment for liver cancer: A case report. (PubMed, World J Clin Oncol) - "Cadonilimab not only treats microsatellite stability gastric cancer patients but can also be used for liver cancer treatment."

IO biomarker • Journal • Cardiovascular • Gastric Cancer • Gastroenterology • Gastrointestinal Disorder • Hepatology • Hypertension • Liver Cancer • Oncology • Portal Hypertension • Solid Tumor

Real-World Efficacy and Safety of Anti-PD-1 Antibody Plus Apatinib and Temozolomide for Advanced Acral Melanoma. (PubMed, Cancer Manag Res) - P2 | "The combination of programmed cell death-1 (PD-1) blockade camrelizumab plus apatinib (an antiangiogenic agent) and temozolomide has displayed promising therapeutic effects in patients with advanced acral melanoma (AM) in a non-randomized Phase II clinical trial (NCT04397770). Overall, 92.4% and 45.2% of the patients experienced any-grade and grade 3-4 TRAEs, respectively. This study provides real-world evidence that support the effectiveness and safety of combined anti-PD-1 antibody, apatinib and temozolomide for treating advanced AM, demonstrating a considerable ORR and prolonged survival, as well as acceptable tolerability."

Journal • Real-world evidence • Melanoma • Oncology • Solid Tumor

Phase II trial of transarterial chemoembolization followed by sintilimab (anti-PD-1), oxaliplatin, and S-1 combined with either trastuzumab (HER-2 positive) or apatinib (HER-2 negative) as first-line therapy for gastric cancer with liver metastases. (ASCO 2025) - P2 | "Clinical Trial Registration Number: ChiCTR2200057726 The abstract will be released to the public on May 22, 2025 at 4:00 PM CDT"

Clinical • P2 data • Gastric Cancer • Hepatology • Oncology • Solid Tumor • HER-2

Immune checkpoint inhibitors plus chemotherapy in the first-line treatment of young unresectable gastric cancer patients: a multicentre real-world study. (PubMed, Front Oncol) - "After screening, 134 patients were included for analysis: 63 received dual chemotherapy (mFOLFOX6, XELOX, SOX and two-drug containing paclitaxel), 32 PD-1 inhibitors plus dual chemotherapy (mFOLFOX6, XELOX, SOX and two-drug containing paclitaxel), and 39 triple regimens (two-drug chemotherapy combined with apatinib or trastuzumab, or triple chemotherapy based on platinum, fluorouracil and paclitaxel)...Young patients with GC have unique clinical characteristics and are not sensitive to immunotherapy. Triple regimens, especially intraperitoneal infusion of paclitaxel followed by intravenous paclitaxel combined with S-1 and apatinib oral therapy, deserve to be studied as first-line therapies."

Checkpoint inhibition • IO biomarker • Journal • Real-world evidence • Gastric Cancer • Oncology • Solid Tumor • HER-2 • PD-L1

Camrelizumab plus low–dose apatinib and pegaspargase followed by radiotherapy for newly diagnosed stage I/II natural killer/T–cell lymphoma: a multicenter phase II study (ICML 2025) - No abstract available

Clinical • P2 data • Hematological Malignancies • Lymphoma • Natural Killer/T-cell Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma

Updated network meta-analysis of first-line systemic therapies for advanced hepatocellular carcinoma: consistent role of TACE (EASL 2025) - " Transarterial chemoembolization (TACE) combined with lenvatinib provided the greatest improvement in OS compared to sorafenib, with a hazard ratio of 0.41 (95% confidence interval, 0.30–0.58), followed by sintilimab+IBI305 (0.57; 0.43–0.75), camrelizumab+rivoceranib (0.62; 0.48–0.80), atezolizumab+bevacizumab (0.66; 0.51– 0.85), lenvatinib+pembrolizumab (0.77; 0.62–0.97), and tremelimumab+durvalumab (0.78; 0.64–0.95). Our first-line analysis consistently scored TACE+lenvatinib best for survival outcomes, followed by various immunotherapy-based combinations in advanced HCC. This hierarchy was sustained in aggressive tumors or hepatitis B carriers."

Metastases • Retrospective data • Hepatitis B • Hepatitis C • Hepatocellular Cancer • Hepatology • Infectious Disease • Oncology • Solid Tumor

CCGLC-001: Combined HAIC, TKI/anti-VEGF and ICIs As Conversion Therapy for Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) - P=N/A | N=300 | Recruiting | Sponsor: Ze-yang Ding, MD | Trial completion date: Dec 2024 ➔ Dec 2025 | Trial primary completion date: Apr 2024 ➔ Jun 2025

Trial completion date • Trial primary completion date • Hepatocellular Cancer • Oncology • Solid Tumor

Integrating quality of life and overall survival to quantify benefit from frontline systemic therapy options in unresectable/advanced hepatocellular carcinoma: a network meta-analysis (EASL 2025) - " Ten studies, enrolling 7,268 patients treated with Sorafenib, Lenvatinib, Nivolumab, Tislelizumab, Durvalumab, Atezolizumab+Bevacizumab, Sintilimab+IBI305, Durvalumab+Tremelimumab, Nivolumab+Ipilimumab, Atezolizumab+Cabozantinib, Lenvatinib+Pembrolizumab, Camrelizumab+Apatinib were included... Atezolizumab plus Bevacizumab was associated with the highest magnitude in reducing the risk of deterioration of most HR-QoL domains compared to other systemic therapies. Integrated assessment of OS with HR-QoL assessed by MDC suggests atezolizumab plus bevacizumab to provide the best balance between QoL preservation and OS benefit compared to other systemic therapy options in unresectable/advanced HCC."

HEOR • Metastases • Retrospective data • Fatigue • Hepatocellular Cancer • Hepatology • Oncology • Pain • Solid Tumor

Comparison of efficacy and safety of lenvatinib vs. apatinib in combination with hepatic arterial infusion chemotherapy and immune checkpoint inhibitors for unresectable intrahepatic cholangiocarcinoma: A multicenter retrospective study. (ASCO 2025) - "The abstract will be released to the public on May 22, 2025 at 4:00 PM CDT"

Checkpoint inhibition • Combination therapy • Retrospective data • Biliary Cancer • Cholangiocarcinoma • Oncology • Solid Tumor

Association of alpha-fetoprotein (AFP) and clinical outcomes in patients with unresectable hepatocellular carcinoma (uHCC) treated with camrelizumab + rivoceranib vs sorafenib (CARES-310) (ESMO-GI 2025) - No abstract available

Clinical • Clinical data • Hepatocellular Cancer • Oncology • Solid Tumor • AFP

Adjuvant apatinib following concurrent chemoradiotherapy in high-risk nasopharyngeal carcinoma: A multicenter, prospective, phase 2 study. (ASCO 2025) - P2 | "Clinical Trial Registration Number: NCT 03612219 The abstract will be released to the public on May 22, 2025 at 4:00 PM CDT"

Clinical • P2 data • Nasopharyngeal Carcinoma • Oncology • Solid Tumor

Camrelizumab plus chemotherapy or apatinib in the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma: A double-cohort phase II study. (ASCO 2025) - P2 | "Clinical Trial Registration Number: NCT05156970 The abstract will be released to the public on May 22, 2025 at 4:00 PM CDT"

Clinical • Metastases • P2 data • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Camrelizumab combined with rivoceranib and TACE in the perioperative treatment of hepatocellular carcinoma: A randomized, open-label multicenter trial. (ASCO 2025) - P3 | "Clinical Trial Registration Number: NCT05613478 The abstract will be released to the public on May 22, 2025 at 4:00 PM CDT"

Clinical • Hepatocellular Cancer • Oncology • Solid Tumor

Neoadjuvant systemic chemotherapy combined with camrelizumab (CAM) and apatinib (APA) for BCLC stage A/B hepatocellular carcinoma (HCC) beyond Milan criteria: An interim analysis of a phase 2 trial. (ASCO 2025) - "Clinical Trial Registration Number: NCT06670107 The abstract will be released to the public on May 22, 2025 at 4:00 PM CDT"

Clinical • P2 data • Hepatocellular Cancer • Oncology • Solid Tumor

STAR-01: A randomized phase III clinical trial comparing PD-1 combined with apatinib and SOX,PD-1 combined with SOX, versus SOX alone in patients with advanced gastric adenocarcinoma. (ASCO 2025) - P4 | "Clinical Trial Registration Number: ChiCTR2000028845 The abstract will be released to the public on May 22, 2025 at 4:00 PM CDT"

Clinical • Metastases • P3 data • Gastric Adenocarcinoma • Gastric Cancer • Oncology • Solid Tumor • PD-1

Perioperative camrelizumab plus apatinib and gemcitabine-oxaliplatin in patients with borderline resectable biliary tract malignancies: A multicenter, single-arm, phase II trial. (ASCO 2025) - P2 | "Clinical Trial Registration Number: NCT05451290 The abstract will be released to the public on May 22, 2025 at 4:00 PM CDT"

Clinical • P2 data • Biliary Cancer • Biliary Tract Cancer • Oncology

Cryoablation combined with camrelizumab and apatinib in advanced hepatocellular carcinoma: A prospective, single-arm, phase II study. (ASCO 2025) - P2 | "Clinical Trial Registration Number: NCT04724226 The abstract will be released to the public on May 22, 2025 at 4:00 PM CDT"

Clinical • Metastases • P2 data • Hepatocellular Cancer • Oncology • Solid Tumor

Updated results of camrelizumab (Cam) plus low dose apatinib combined with gemcitabine and cisplatin (GP) as first-line therapy for advanced biliary tract cancer (BTC): A single center, phase Ib/II trial. (ASCO 2025) - P1/2 | "Clinical Trial Registration Number: NCT05742750 The abstract will be released to the public on May 22, 2025 at 4:00 PM CDT"

Clinical • Metastases • P1/2 data • Biliary Cancer • Biliary Tract Cancer • Oncology • Solid Tumor

Camrelizumab plus apatinib and chemotherapy as neoadjuvant therapy for triple negative breast cancer (TNBC): A single-arm, prospective phase II study (MA-BC-II-026). (ASCO 2025) - P2 | "Clinical Trial Registration Number: NCT05447702 The abstract will be released to the public on May 22, 2025 at 4:00 PM CDT"

Clinical • P2 data • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Neoadjuvant camrelizumab plus apatinib and temozolomide for resectable stage II/III acral melanoma: The CAP 03-NEO trial. (ASCO 2025) - P2 | "Clinical Trial Registration Number: NCT05512481 The abstract will be released to the public on May 22, 2025 at 4:00 PM CDT"

Clinical • Melanoma • Oncology • Solid Tumor